Immunological features of Pneumocystis carinii infection in humans

Affiliations

Review

P D Walzer. Clin Diagn Lab Immunol. 1999 Mar.

. 1999 Mar;6(2):149-55.

doi: 10.1128/CDLI.6.2.149-155.1999.

¹ Veterans Affairs Medical Center, Cincinnati, Ohio 45220, USA. Peter.Walzer@UC.edu

No abstract available

References

1. Agostini C, Adami F, Poulter L W, Israel-Biet D, Freitas e Costa M, Cipriani A, Sancetta R, Lipman M C, Juvin K, Teles-Araujo A D, Cadrobbi P, Masarotto G, Semenzato G. Role of bronchoalveolar lavage in predicting survival of patients with human immunodeficiency virus infection. Am J Respir Crit Care Med. 1997;156:1501–1507. - PubMed
1. Angelici E, Contini C, Romani R, Epifano O, Serra P, Canipari R. Production of plasminogen activator and plasminogen activator inhibitors by alveolar macrophages in control subjects and AIDS patients. AIDS. 1996;10:283–290. - PubMed
1. Angus C W, Tu A, Vogel P, Qin M, Kovacs J A. Expression of variants of the major surface glycoprotein of Pneumocystis carinii. J Exp Med. 1996;183:1229–1234. - PMC - PubMed
1. Armstrong M Y K, Cushion M T. Animal models. In: Walzer P D, editor. Pneumocystis carinii pneumonia. New York, N.Y: Marcel Dekker; 1994. pp. 181–222.
1. Barltett M S, Angus W C, Shaw M M, Durant P J, Lee C H, Pascale J M, Smith J W. Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia. Clin Diagn Lab Immun. 1998;5:74–77. - PMC - PubMed